Table 5.

MDSS-based bridges for JIA domain

Disease	ProteinGene	Score	S
anemias	erythropoietin	coh = 0.500	2
psoriasis	TNF human	coh = 0.333	2
psoriasis	fusion protein	conf = 0.333	3
periodic syndrome	TNF receptors	coh = 1.000	2
systemic onset JIA	receptors IL-6	coh = 0.114	8
rickets celiac	gluten	coh = 0.500	2
tuberculous infections	TNF blockers infliximab	conf = 0.222	2
ACLS (*)	lupus coagulation inhibitor	f1 = 0.500	2
third disease	vaccine rubella	conf = 1.000	3
diseases autoimmune	tyrosine phosphatases protein	coh = 0.500	2
syndrome laron	insulinlike growth factor	conf = 1.000	2
disorder amyloid	substance amyloid	f1 = 0.141	5
osteoarthrosis oa	proteoglycans	f1 = 0.188	3
growth failure	insulinlike growth factor	conf = 0.667	2
thyromegaly	substance amyloid	conf = 0.600	3
syndrome macrophage activation	perforin	coh = 0.571	4
syndrome macrophage activation	cyclosporine medication	f1 = 0.311	14
uveitis	factors antinuclear	conf = 0.171	19
systemic JIA	IL-1 receptor antagonist protein	conf = 0.133	2
syndrome hemophagocytic	perforin	coh = 0.286	2
eye disease cataract	factors antinuclear	conf = 0.250	15
myasthenia gravis	acetylcholine receptor	coh = 1.000	2

Best δ-maximum scored bridges between the Disease and ProteinGene levels for the the JIA domain, using our reduction method (MDSS). Interestingness measures used are: cohesion (coh), confidence (conf) and f-measure (f1). The column S indicates the number of documents supporting each bridge.